HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.

Abstract
All randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper. The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence quality of the studies included. Four RCTs involving 1407 patients with RA were included. Meta-analyses showed that, after 24-week therapy, ACR20, tender joint count, swollen joint count, rest pain, physician and patient global assessment of disease activity, HAQ score, ESR, and CRP in iguratimod group were better than those in placebo group and that the difference between those of iguratimod group and those of other DMARDs (MTX and SASP) group was not significant. GRADE evidence classification of the studies included was moderate. Iguratimod for RA had few adverse events, and its efficacy and safety were the same as those of MTX and SASP for RA. The results of this systematic review suggest that more high-quality and large-scaled RCTs were needed to determine the efficacy of iguratimod for RA and whether iguratimod is as effective as other DMARDs besides MTX and SASP.
AuthorsJiangtao Li, Hejuan Mao, Yan Liang, Yanrong Lu, Shuo Chen, Nanping Yang, Guixiu Shi
JournalClinical & developmental immunology (Clin Dev Immunol) Vol. 2013 Pg. 310628 ( 2013) ISSN: 1740-2530 [Electronic] Egypt
PMID24371446 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Chemical References
  • Chromones
  • Immunosuppressive Agents
  • Sulfonamides
  • iguratimod
Topics
  • Arthritis, Rheumatoid (diagnosis, drug therapy)
  • Chromones (adverse effects, therapeutic use)
  • Humans
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Odds Ratio
  • Randomized Controlled Trials as Topic
  • Sulfonamides (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: